@misc{oai:repo.qst.go.jp:00063992,
 author = {Hasegawa, Azusa and Koto, Masashi and Takagi, Ryo and Morikawa, Takamichi and Kamada, Tadashi and Mizoe, Junetsu and Tsujii, Hirohiko and 長谷川 安都佐 and 小藤 昌志 and 高木 亮 and 森川 貴迪 and 鎌田 正 and 溝江 純悦 and 辻井 博彦},
 month = {Sep},
 note = {1. Skull Base and Paracervical Tumors
Abstract
To estimate the toxicity and efficacy of the clinical trials for patients with skull base and paracervical tumors treated with carbon ion radiotherapy.
A phase I/II dose escalation study for skull base and paracervical tumor was initiated in April 1997. The phase I/II dose escalation trial was performed up to the fourth-stage dose level. From April 2004, a phase II clinical trial was initiated under the Highly Advanced Medical Technology scheme with an irradiation schedule of 60.8 GyE in 16 fractions over four weeks.
At the time of analysis, there was no evidence of any serious acute or late reactions in skull base and paracervical tumors. For skull base and paracervical tumor, the carbon ion dose in excess of 57.6 GyE improves local control. 
\n2. Head-and-Neck Tumors
Abstract
To evaluate the efficacy of carbon ion radiotherapy for malignant head-and-neck tumors.
Between April 1997 and February 2010, 378 cases with locally advanced, histologically proven, and new or recurrent malignant tumors of the head-and-neck were treated with carbon ions. Treatment dose was 64.0 GyE in 16 fractions over 4 weeks (or 57.6 GyE when a wide area of skin was included in the target volume).
There were no acute reactions worse than grade 3 and no late toxicities worse than grade 2. The five-year local control and overall survival rates were 75% and 54%, respectively. But the five-year local control rate was 25% for bone and soft tissue sarcomas, and the five-year overall survival rate was 36% for malignant melanomas. 
Carbon ion radiotherapy for malignant head-and-neck tumors can be described as presenting no clinical problems. Although local control of carbon ion radiotherapy was promising for malignant head-and-neck tumor excluding sarcoma, the survival rate was not commensurate with the favorable local control rate of malignant melanoma. On the basis of the results of the analysis, this part of the study was divided into two additional protocols, one for bone and soft tissue sarcomas and another for mucosal malignant melanomas., The 4th Japanese-European Joint Symposium on Ion Cancer Therapy},
 title = {Carbon Ion Radiotherapy for Skull Base and Head-and-Neck Tumors},
 year = {2010}
}